JP2739110B2 - ヒト乳ガンの分析 - Google Patents

ヒト乳ガンの分析

Info

Publication number
JP2739110B2
JP2739110B2 JP62025563A JP2556387A JP2739110B2 JP 2739110 B2 JP2739110 B2 JP 2739110B2 JP 62025563 A JP62025563 A JP 62025563A JP 2556387 A JP2556387 A JP 2556387A JP 2739110 B2 JP2739110 B2 JP 2739110B2
Authority
JP
Japan
Prior art keywords
breast cancer
antigen
serum
monoclonal antibody
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP62025563A
Other languages
English (en)
Japanese (ja)
Other versions
JPS62259064A (ja
Inventor
エス．リンズレイ ピーター
ダブリュ．オクス ヴィンセント
ホーン ダイアン
ピー．ブラウン ジョセフ
ビー．リング デイビッド
イー．フランケル アーサー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25246638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2739110(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of JPS62259064A publication Critical patent/JPS62259064A/ja
Application granted granted Critical
Publication of JP2739110B2 publication Critical patent/JP2739110B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP62025563A 1986-02-05 1987-02-05 ヒト乳ガンの分析 Expired - Lifetime JP2739110B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US826477 1986-02-05
US06/826,477 US4803169A (en) 1986-02-05 1986-02-05 Assay for human breast cancer

Publications (2)

Publication Number Publication Date
JPS62259064A JPS62259064A (ja) 1987-11-11
JP2739110B2 true JP2739110B2 (ja) 1998-04-08

Family

ID=25246638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62025563A Expired - Lifetime JP2739110B2 (ja) 1986-02-05 1987-02-05 ヒト乳ガンの分析

Country Status (9)

Country Link
US (1) US4803169A (enExample)
EP (1) EP0232179B1 (enExample)
JP (1) JP2739110B2 (enExample)
AT (1) ATE78601T1 (enExample)
AU (1) AU593476B2 (enExample)
CA (1) CA1279006C (enExample)
DE (1) DE3780480T2 (enExample)
ES (1) ES2033823T3 (enExample)
GR (1) GR3005971T3 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861511B1 (en) 1986-06-04 2005-03-01 Bayer Corporation Detection and quantification of neu related proteins in the biological fluids of humans
US5401638A (en) * 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
AU613590B2 (en) * 1986-11-19 1991-08-08 Bristol-Myers Squibb Company Hybridomas producing monoclonal antibodies to new mucin epitopes
US6004761A (en) * 1986-11-19 1999-12-21 Sanofi Method for detecting cancer using monoclonal antibodies to new mucin epitopes
EP0394510A1 (en) * 1989-04-24 1990-10-31 Mochida Pharmaceutical Co., Ltd. Method for assaying a tumor-associated antigen in a minute amount of nipple discharge and device for such an assay
AU656716B2 (en) * 1989-09-15 1995-02-16 Genetic Systems Corporation Hybridoma CT43 producing a monoclonal antibody to a mucin epitope of colorectal cancer
US5411868A (en) * 1989-10-24 1995-05-02 Board Of Regents, The University Of Texas System Diagnostic and premonitoring uses of a 65 kDa tumor-associated protein in companion and domestic animal malignancy
AU7316391A (en) * 1990-01-25 1991-08-21 State of Oregon acting by and through the The State Board of Higher Education on Behalf of the Oregon Health Sciences University, The Detection of a characteristic antigen from carcinoma in body fluids
US5256540A (en) * 1990-12-28 1993-10-26 Mayo Foundation For Medical Education And Research Immunoassay for small cell lung carcinoma
DE69332642T2 (de) * 1992-10-29 2003-10-02 Thomas Jefferson University, Philadelphia Methoden zur detektion von mikrometastasen bei prostata-krebs
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
US5763164A (en) * 1993-04-16 1998-06-09 Northwestern University Immunogenic cancer proteins and peptides and methods of use
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522918A (en) * 1981-12-15 1985-06-11 Jeffery Schlom Process for producing monoclonal antibodies reactive with human breast cancer
EP0087898A1 (en) * 1982-02-22 1983-09-07 Cancer Research Campaign Technology Limited Antibodies and antigens useful in the diagnosis and treatment of cancer
US4657851A (en) * 1984-01-03 1987-04-14 Georgetown University Breast cancer diagnostic blood test
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
DE3586216T2 (de) * 1984-05-01 1992-12-10 Ciba Corning Diagnostics Corp Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
WO1986004092A1 (fr) * 1984-12-28 1986-07-17 Taisho Pharmaceutical Co., Ltd. Procede de preparation d'un anticorps monoclonal specifique du cancer humain
AU601379B2 (en) * 1985-11-07 1990-09-13 Trustees Of Columbia University In The City Of New York, The Antigen indicative of human breast cancer and assays based thereon

Also Published As

Publication number Publication date
ATE78601T1 (de) 1992-08-15
ES2033823T3 (es) 1993-04-01
AU593476B2 (en) 1990-02-08
EP0232179B1 (en) 1992-07-22
CA1279006C (en) 1991-01-15
DE3780480D1 (de) 1992-08-27
AU6828387A (en) 1987-08-06
GR3005971T3 (enExample) 1993-06-07
EP0232179A3 (en) 1989-09-06
DE3780480T2 (de) 1993-02-18
EP0232179A2 (en) 1987-08-12
JPS62259064A (ja) 1987-11-11
US4803169A (en) 1989-02-07

Similar Documents

Publication Publication Date Title
EP3149042B1 (en) Pd-l1 antibodies and uses thereof
JP2739110B2 (ja) ヒト乳ガンの分析
AU661332B2 (en) Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
JP2012524521A (ja) グリコデリンモノクローナル抗体および卵巣癌の検出におけるその使用のための方法
US5288614A (en) Method for the detection of malignant diseases
US5512657A (en) Detection of complexes which include basement membrane components as diagnostic of cancer and other diseases
KR20170029414A (ko) 암을 스크리닝하고 검출하는 방법 및 조성물
WO1996028569A1 (en) Monoclonal antibody and antigen relating to human pulmonary adenocarcinoma and immunoassay method with the use of the same
Klug et al. Confirmation of a false-positive result in CA 125 immunoradiometric assay caused by human anti-idiotypic immunoglobulin.
EP0767381A1 (en) Detection, quantification and classification of ras proteins in body fluids and tissues
EP0747705A1 (en) Specific determination of NCA 90 glycoform in the blood of cancer patients
EP1213302B1 (en) Specific antibody directed to active but not inactive hepatocyte growth factor activator (HGFA)
Kim et al. Monoclonal antibody PR92 with restricted specificity for tumor-associated antigen of prostate and breast carcinoma
CN111303289A (zh) 抗人Tn型糖基化MUC1抗体及其用途
WO1997008549A1 (fr) Procede de detection d'affections renales, produit et kit de diagnostic appropries
Matsuoka et al. Evaluation of a new monoclonal radioimmunoassay system for carcinoembryonic antigen
WO1992004464A2 (en) Monoclonal antibodies against tenascin
Okazaki et al. Serum type III procollagen peptide: Indicator for pulmonary fibrosis I. A tool for early detection of pulmonary fibrosis as a complication in cancer therapy
JPS62201364A (ja) 高分子量　癌胎児性抗原の免疫検定法
AU652192B2 (en) Diagnostic method
JP4803943B2 (ja) 肝細胞増殖因子活性化因子阻害因子−１に対する抗体とその用途
JP2018062466A (ja) 新規甲状腺癌関連抗原に結合する抗体および甲状腺癌診断剤
EP0710362B1 (en) Methods for determining the invasiveness of a bladder tumor
EP1262492A1 (en) Antibody to hepatocyte growth factor activator inhibitor-1 and use thereof
CN111208304A (zh) 肿瘤来源IgG在甲状旁腺癌诊断和预后中的用途

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term